Jubilant Radiopharma Revenue and Competitors
Estimated Revenue & Valuation
- Jubilant Radiopharma's estimated annual revenue is currently $131.1M per year.
- Jubilant Radiopharma's estimated revenue per employee is $201,000
Employee Data
- Jubilant Radiopharma has 652 Employees.
- Jubilant Radiopharma grew their employee count by 5% last year.
Jubilant Radiopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $43.2M | 215 | 6% | N/A | N/A |
#2 | $81.8M | 407 | 10% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 223 | 1% | N/A | N/A |
#6 | $13.1M | 65 | 5% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 86 | -5% | N/A | N/A |
#9 | $67.9M | 338 | 23% | N/A | N/A |
#10 | $14.9M | 74 | 7% | N/A | N/A |
What Is Jubilant Radiopharma?
Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of Improving Lives Through Nuclear Medicine on a global scale.
keywords:N/A
N/A
Total Funding
652
Number of Employees
$131.1M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Jubilant Radiopharma News
Meanwhile, Jubilant Pharmova shares have gained after two days of fall. ... The Radiopharma business is also expected to deliver a muted...
Jubilant Pharmova's latest shareholding pattern shows that Rakesh ... The Radiopharma business is also expected to deliver a muted...
Singapore-based Jubilant Pharma has presence in the niche specialty (radiopharma and allergy therapy products) pharmaceuticals,...
Other Companies in Morrisville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 704 | 33% | N/A |
#2 | $169.7M | 836 | N/A | N/A |
#3 | $172.5M | 858 | -1% | N/A |
#4 | $194.5M | 958 | 15% | N/A |
#5 | $507M | 1026 | 8% | N/A |